Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Traditional Chinese medicine 1 is a herbal prescription developed by Qianfoshan Hospital for the prevention of hepatic encephalopathy in patients with hepatitis B-related cirrhosis who have undergone transjugular intrahepatic portosystemic shunt (TIPS) surgery. TIPS is a procedure used to treat portal hypertension but carries a high risk of hepatic encephalopathy due to the shunting of neurotoxic substances, such as ammonia and endotoxins, away from the liver's detoxification process. This TCM formula is designed to address the 'liver-gut axis' by enhancing the intestinal mucosal barrier and modulating the gut microbiota to reduce the production and translocation of these toxins. It is currently being evaluated in a Phase 3 clinical trial as part of an integrated Chinese and Western medicine treatment protocol.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on traditional chinese medicine 1-Qianfoshan Hospital-hepatic encephalopathy.